Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 164
- Registration Number
- NCT06860490
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Phase 2
Recruiting
- Conditions
- Soft Tissue SarcomasAngiosarcomaFibrosarcomaLeiomyosarcomaPleomorphic LiposarcomaMalignant Peripheral Nerve Sheath Tumor (MPNST)Desmoplastic Small Round Cell Tumor
- Interventions
- Drug: Tislelizumab+liposomal doxorubicin+ifosfamide
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 45
- Registration Number
- NCT06849986
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Not Applicable
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer MetastaticMelanoma Metastatic
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 66
- Registration Number
- NCT06889610
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)(SURVEILLANCE-I)
Not yet recruiting
- Conditions
- Colorectal Cancer (CRC)
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 390
- Registration Number
- NCT06879873
MRD-Guided Surveillance in Resectable Stage IV Metastatic Colorectal Cancer (SURVEILLANCE-II)
Not yet recruiting
- Conditions
- Colorectal Cancer (CRC)Colorectal Cancer Liver Metastases (CRLM)
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 181
- Registration Number
- NCT06879886
MRD-Guided Surveillance in Locally Advanced Mid-Low Rectal Cancer (SURVEILLANCE-III)
Not yet recruiting
- Conditions
- Colorectal Cancer (CRC)
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 139
- Registration Number
- NCT06879899
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)
Phase 2
Recruiting
- Conditions
- Intrahepatic Cholangiocellular Carcinoma
- Interventions
- Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)Procedure: cryoablation
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 92
- Registration Number
- NCT06860477
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined with Local Treatment in Advanced Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- Drug: TAS-102+bevacizumab+local treatmentDrug: Standard chemotherapy
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 119
- Registration Number
- NCT06856187
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
Not Applicable
Recruiting
- Conditions
- Advanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy
- Interventions
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT06856200
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, China
Predicting Gastric Neoplasia in Patients with High-risk Endoscopic Features
Not yet recruiting
- Conditions
- Gastric Neoplasia
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2700
- Registration Number
- NCT06853509
- Locations
- 🇨🇳
Huadong hospital affiliated to Fudan university, Shanghai, Shanghai, China